Changes of Lipid and Lipoprotein Compositions in Kawasaki Disease and its Impact on Cardiac Complications |
Yun, Sin Weon
(Department of Pediatrics, College of Medicine, Chung-Ang University)
Lee, Ho Seok (Department of Pediatrics, College of Medicine, Chung-Ang University) Kim, Dong Woon (Department of Pediatrics, College of Medicine, Chung-Ang University) Rhee, Kang Won (Department of Pediatrics, College of Medicine, Chung-Ang University) Jung, Young Soo (Department of Pediatrics, College of Medicine, Chung-Ang University) |
1 | Choi SM, Choi JH. Levels of serum HDL-cholesterol and total cholesterol in Kawasaki disease and their significance. Korean Circ J 1997;27:1298-302 DOI |
2 | Stein EA, Myers G. Lipid, apolipoproteins, and lipoproteins In : Burtis CA, Ashwood ER. Trietz fundamentals of clinical chemistry. 4th ed. Philadelphia : WB Saunders, 1996:375-401 |
3 | Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr int 2002;44:1-4 DOI ScienceOn |
4 | Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997;42:651-5 DOI ScienceOn |
5 | Salo E, Pesonen E, Viikari J. Serum cholesterol levels during and after kawasak disease. J Pediatr 1991;119:557-61 DOI PUBMED |
6 | Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, et al. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation Crit Care Med 2004;32: 632-7 DOI ScienceOn |
7 | Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness : Implications for preventing and treating endotoxemia. Crit Care Med 1996;24:584-9 DOI ScienceOn |
8 | Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, et al. Active Remodeling of the coronary arterial lesions in the late phase of Kawasaki disease immunohistochemical study. Circulation 2000;101:2935-41 DOI ScienceOn |
9 | Hsieh KS, Weng KP, Lin CC, Hwang DC, Liu WS, Chen FL. The serial change of serum lipid profile in Kawasaki disease. Chest 1997;112:66S |
10 | Kawasaki T. Acute febrile mucocutaneous lymph node syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J allergy 1967;16:178-222 |
11 | Fahie-Wilson M, Mills R, Wilson K. HDL cholesterol and the acute phase reaction following myocardial infarction and acute pancreatitis. Clin Chim Acta 1987;167:197-209 DOI ScienceOn |
12 | Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MM, Jansen J, Wouter ten Cate J, et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997; 90:1415-24 |
13 | Newburger JW. Kawasaki disease : Who is at risk? (Editorial) J Pediatr 2000;137:149-52 DOI PUBMED ScienceOn |
14 | Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CCL, et al. Changes in plasma level of lipids and lipoprotein composition in patients aith Kawasaki disease. Clinic Chimica Acta 1997;260:15-26 DOI ScienceOn |
15 | Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease : Can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-44 DOI ScienceOn |
16 | Lee YJ, Lee YS, Hyun MC, Lee SB. Lipid profile changes in Kawasaki disease patients. J Korean Pediatr Soc 2000; 43:216-22 |
17 | Silva AA, Maeno Y, Hasbmi A, Smallborn JF, Silverman ED, McCrindle BW. Cardiovascular risk factors after Kawasaki disease a case-control study. J Pediatr 2001;138: 400-5 DOI ScienceOn |
18 | Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1 and tumor necrosis factor alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381-9 DOI PUBMED ScienceOn |
19 | Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the national heart, lung, and blood institute workshop on Lipoprotein(a) and cardiovascular disease: Recent advances and future directions. Clin Chem 2003;49: 1785-96 DOI ScienceOn |
20 | Noto N, Okada T, Yamasuge M, Taniguchi K, Karasawa K, Ayusawa M, et al. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001;107: 1095-9 DOI PUBMED ScienceOn |
21 | Okada T, Harada K, Okuni M. Serum HDL-cholesterol and lipoprotein fraction in Kawasaki disease(acute mucocutaneous lymphnode syndrome). Jpn Circ J 1982;46:1039-42 DOI ScienceOn |
22 | Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84: 625-31 DOI ScienceOn |
23 | Van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359-66 DOI ScienceOn |
24 | Senzaki H, Chen CH, Ishido H, Masutani S, Matsunaga T, Taketazu M, et al. Arterial hemodynamics in patients after Kawasaki disease. Circulation 2005;111:2119-25 DOI ScienceOn |
25 | Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK. Novel and traditional cardiovascular risk factors in children after Kawasaki disease. Implications for premature atherosclerosis. J Am Coll Cardiol 2004;43:120-4 DOI ScienceOn |
26 | Berg K. Immunochemical studies of the Lp(a) factor. Acta Pathol Microbiol Scand 1964;62:600-12 DOI |
27 | Dhillon R, Clarkson P, Donald AE, Powe AJ,Nash M, Novelli V, Dillon MJ, Deanfield JE. Endothelial dysfunction late after Kawasaki disease. Circulation 1996;94:2103-6 DOI ScienceOn |
28 | Fraunberger P, Nagel D, Walli AK, Seidel D, Walli K, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med 2000;28:3574-5 DOI ScienceOn |
29 | McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein( a) is homologous to plasminogen. Nature 1987;330: 132-7 DOI ScienceOn |